Bionano Genomics Sees 56% Rise in Rare Disease OGM Publications, 225% Sample Growth
28 rare disease publications in Q1 2026 represent a 56% increase as Bionano Genomics analyzed 78 samples, up 225% from 24 in Q1 2025. Global studies demonstrate OGM uncovers structural variants overlooked by traditional methods, boosting its adoption for resolving unsolved cases and identifying actionable gene disruptions.
1. Publication Growth
Bionano Genomics reported 28 publications describing the utility of OGM in rare disease research during Q1 2026, a 56% increase compared to Q1 2025. These studies originate from institutions across Europe, Asia, South America and the United States.
2. Sample Volume Surge
The total number of samples analyzed in these studies reached 78, marking a 225% increase from the 24 samples reported in Q1 2025. This surge highlights growing research scale and confidence in OGM’s ability to handle larger datasets.
3. OGM Research Impact
Multiple studies demonstrate that OGM can identify structural variants often missed by traditional cytogenetic methods and sequencing, increasing diagnostic yield by up to 17% in some cohorts. It has effectively characterized complex rearrangements and pinpointed actionable gene disruptions across neuromuscular, neurodevelopmental and immunological conditions.
4. Implications for Bionano
The expanding publication volume and sample throughput reinforce OGM’s positioning as a complementary or gold standard tool for genomic research, potentially accelerating its adoption among clinical and research laboratories. Increased validation through peer-reviewed studies may drive greater licensing and service revenue for Bionano.